Navigation Links
Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair
Date:1/22/2008

CLINTON, N.J., Jan. 22 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that Lota S. Zoth has been elected as an independent member of the company's Board of Directors. Ms. Zoth, the former Chief Financial Officer of MedImmune, will chair the Ikaria Audit Committee.

"We are very fortunate to have an executive with Lota's background and qualifications joining our Board at a very important time in the company's history," said David Shaw, Chairman of the Ikaria Board of Directors. "Lota's deep understanding of financial and accounting issues, in addition to her senior leadership experience in the pharmaceutical business, make her a superb fit for Ikaria."

Ms. Zoth served as MedImmune's Chief Financial Officer from 2004 until mid 2007, when MedImmune was acquired by AstraZeneca. Prior to that, Ms. Zoth served as Chief Accounting Officer of MedImmune, PSINet and Sodexho Marriott, all publicly traded companies. Ms. Zoth began her career as an auditor with Ernst & Young, and went on to management positions in financial reporting and controllership at PepsiCo and Marriott International. Ms. Zoth is a CPA, and holds a BBA, summa cum laude, in accounting from Texas Tech University.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations for the critically ill. The company's product, INOmax(R) (nitric oxide) for inhalation, is an FDA- approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to marketing and selling its INOmax product, Ikaria is engaged in both Phase II trials with Covox(R) (carbon monoxide) for inhalation and Phase I trials with hydrogen sulfide (H2S) for various indications. Ikaria has a staff of over 300 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Ikaria, please visit http://www.ikaria.com.

CONTACTS

Elizabeth Larkin Jason Rando

Ikaria The Ruth Group

908-238-6645 646-536-7025

liz.larkin@ikaria.com jrando@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bruce Pasternack Elected to Codexis Board
2. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
3. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
4. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
5. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
6. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
7. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
8. Solazyme Selected for National Institute of Standards and Technology Award
9. Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America
10. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
11. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):